Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study.
Schleicher S, Moore A, Rafal E, Gagne-Henley A, Johnson SM, Dhawan S, Chavda R, York JP, Sforzolini B, Holcomb K, Ablon G, Del Rosso J, Dreno B. Schleicher S, et al. Among authors: gagne henley a. Dermatol Ther (Heidelb). 2023 Dec;13(12):3085-3096. doi: 10.1007/s13555-023-01042-7. Epub 2023 Oct 15. Dermatol Ther (Heidelb). 2023. PMID: 37838987 Free PMC article.
Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison.
Dréno B, Bissonnette R, Gagné-Henley A, Barankin B, Lynde C, Kerrouche N, Tan J. Dréno B, et al. Among authors: gagne henley a. Am J Clin Dermatol. 2018 Apr;19(2):275-286. doi: 10.1007/s40257-018-0352-y. Am J Clin Dermatol. 2018. PMID: 29549588 Free PMC article. Clinical Trial.
Long-Term Effectiveness and Safety of Up to 48 Weeks' Treatment with Topical Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in the Prevention and Reduction of Atrophic Acne Scars in Moderate and Severe Facial Acne.
Dréno B, Bissonnette R, Gagné-Henley A, Barankin B, Lynde C, Chavda R, Kerrouche N, Tan J. Dréno B, et al. Among authors: gagne henley a. Am J Clin Dermatol. 2019 Oct;20(5):725-732. doi: 10.1007/s40257-019-00454-6. Am J Clin Dermatol. 2019. PMID: 31209851 Clinical Trial.
Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS).
Lynde CW, Alam MS, Ohson K, Gagné-Henley A, Avadisian M, Vender RB. Lynde CW, et al. Among authors: gagne henley a. Dermatol Ther (Heidelb). 2022 Apr;12(4):921-931. doi: 10.1007/s13555-022-00703-3. Epub 2022 Mar 14. Dermatol Ther (Heidelb). 2022. PMID: 35286612 Free PMC article.
Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
Bissonnette R, Haydey R, Rosoph LA, Lynde CW, Bukhalo M, Fowler JF, Delorme I, Gagné-Henley A, Gooderham M, Poulin Y, Barber K, Jenkin P, Landells I, Pariser DM. Bissonnette R, et al. Among authors: gagne henley a. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):403-410. doi: 10.1111/jdv.14647. Epub 2017 Nov 15. J Eur Acad Dermatol Venereol. 2018. PMID: 29055155 Clinical Trial.
Correction: Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study.
Schleicher S, Moore A, Rafal E, Gagne-Henley A, Johnson SM, Dhawan S, Chavda R, York JP, Sforzolini B, Holcomb K, Ablon G, Del Rosso J, Dreno B. Schleicher S, et al. Among authors: gagne henley a. Dermatol Ther (Heidelb). 2024 Feb;14(2):559-561. doi: 10.1007/s13555-023-01090-z. Dermatol Ther (Heidelb). 2024. PMID: 38216821 Free PMC article. No abstract available.